Zobrazeno 1 - 10
of 46
pro vyhledávání: '"C. Llagostera"'
Autor:
V. Potiron, G. Delpon, L. Ollivier, L. Vaugier, M. Doré, V. Guimas, E. Rio, F. Thillays, C. Llagostera, A. Moignier, S. Josset, S. Chiavassa, T. Perennec, S. Supiot
Publikováno v:
Cancer/Radiothérapie. 26:808-813
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::509ae0c6e9813ec437f68d5f7efce51b
https://doi.org/10.1016/j.canrad.2022.07.009
https://doi.org/10.1016/j.canrad.2022.07.009
Autor:
A. Lisbona, C. Llagostera
Publikováno v:
Cancer/Radiothérapie. 26:814-817
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::603b2d275fc6f26ad54f63be8787fe85
https://doi.org/10.1016/j.canrad.2022.06.022
https://doi.org/10.1016/j.canrad.2022.06.022
Autor:
A, Lisbona, C, Llagostera
Publikováno v:
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. 26(6-7)
Quality assurance for radiotherapy of a clinical trial is an important step from the design of the clinical trial. A precise definition of quality assurance must be given in detail in the clinical protocol of the clinical trial. By its implementation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::beca6e54d15da0ae3a989b4a4f8ab8e7
https://pubmed.ncbi.nlm.nih.gov/36050203
https://pubmed.ncbi.nlm.nih.gov/36050203
Autor:
V, Potiron, G, Delpon, L, Ollivier, L, Vaugier, M, Doré, V, Guimas, E, Rio, F, Thillays, C, Llagostera, A, Moignier, S, Josset, S, Chiavassa, T, Perennec, S, Supiot
Publikováno v:
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. 26(6-7)
Translational research in radiation oncology is undergoing intense development. An increasingly rapid transfer is taking place from the laboratory to the patients, both in the selection of patients who can benefit from radiotherapy and in the develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::092da6980b5332f27ac5a85a1fdd6cb8
https://pubmed.ncbi.nlm.nih.gov/35999162
https://pubmed.ncbi.nlm.nih.gov/35999162
Autor:
O. Henry, S. Perrot, F. Le Vigouroux, E. Martin, T. Prodhomme, F. Jouyaux, M. Getain, E. Biron, S. Collet, P. Gesnouin, C. Leleu, A. Vela, S. Martineau, C. Le Prince, M. Benchalal, P. Lecoeur, J. Palisson, F. Coste, G. L’Haridon P. Le Dorze, S. Danhier, C. Llagostera
Publikováno v:
Physica Medica. 68:13-15
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b429ec7486e0ad9ec66b2bef0a093c25
https://doi.org/10.1016/j.ejmp.2019.09.103
https://doi.org/10.1016/j.ejmp.2019.09.103
Autor:
C. Llagostera, Y. Kirova, S. Batard, S. Belhomme, M. A. Mahé, Philippe Moreau, P. Meyer, D. Antoni, Bruno Lioure, Noel-Jean Milpied
Publikováno v:
Total Marrow Irradiation ISBN: 9783030386917
Despite advances in drug treatments, multiple myeloma almost always remains a fatal disease. Technical advances in radiotherapy enable total marrow irradiation (TMI) by intensity-modulated radiation therapy (IMRT) to better protect healthy tissues an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21db3e4b85b855b20dcfe3be7d73df1a
https://doi.org/10.1007/978-3-030-38692-4_9
https://doi.org/10.1007/978-3-030-38692-4_9
Publikováno v:
Physica Medica. 68:20-21
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::400425e40a72ee63cb0bc3e2d9f12005
https://doi.org/10.1016/j.ejmp.2019.09.114
https://doi.org/10.1016/j.ejmp.2019.09.114
Autor:
M. Voyeau, C. Llagostera, Albert Lisbona, A. Moignier, Gregory Delpon, Sophie Chiavassa, S. Josset, P. Onoma
Publikováno v:
Physica Medica. 68:23
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b60ca8ea4a40358b88ac03e28ed9c3de
https://doi.org/10.1016/j.ejmp.2019.09.119
https://doi.org/10.1016/j.ejmp.2019.09.119
Autor:
Gilles Créhange, C Llagostera, C Bonin, S. Belhomme, P. Sargos, R. de Crevoisier, Caroline Lafond, Christophe Hennequin, G. Delaroche, J Langrand-Escure, David Pasquier, Stéphane Supiot, I. Latorzeff, F Bideault
Publikováno v:
Cancer Radiothérapie
Cancer Radiothérapie, Elsevier Masson, 2018, 22 (2), pp.193-198. ⟨10.1016/j.canrad.2017.11.004⟩
Cancer/Radiothérapie
Cancer/Radiothérapie, 2018, 22 (2), pp.193-198. ⟨10.1016/j.canrad.2017.11.004⟩
Cancer Radiothérapie, Elsevier Masson, 2018, 22 (2), pp.193-198
Cancer Radiothérapie, Elsevier Masson, 2018, 22 (2), pp.193-198. ⟨10.1016/j.canrad.2017.11.004⟩
Cancer/Radiothérapie
Cancer/Radiothérapie, 2018, 22 (2), pp.193-198. ⟨10.1016/j.canrad.2017.11.004⟩
Cancer Radiothérapie, Elsevier Masson, 2018, 22 (2), pp.193-198
International audience; Considering recent phase III trials results, moderate hypofractionated radiotherapy can be considered as a standard treatment for low and intermediate risk prostate cancer management. This assessment call for a framework allow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80b3a3081382f62076bf25ed8d29933f
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01807361
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01807361
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.